Login to Your Account



Austrian Start-up Ugichem Tackles RNA Delivery Issue

By Nuala Moran
Staff Writer

Tuesday, August 20, 2013
LONDON – In the past year the lure of gene silencing as a route to address disease has prompted a revival in the field. But it remains the case that the difficulties of delivering RNA-based drugs continue to slow the pace of development and limit their use to the liver or tumor tissues, or to tissues where local administration is possible.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription